PML: An emerging tumor suppressor and a target with therapeutic potential

Eric L. Reineke, Huang Ying Kao

研究成果: Review article

16 引文 (Scopus)

摘要

Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Many of these effects are due to changes in the transcriptional profile of the cell as a result of decreased size and number of PML nuclear bodies. Several mouse studies confirm the contribution of PML to oncogenesis and cancer progression. It is important to not only further define a role for PML as a tumor suppressor, but also to begin to develop strategies to target PML therapeutically.

原文English
頁(從 - 到)219-226
頁數8
期刊Cancer Therapy
7
發行號ISSUE A
出版狀態Published - 2009 一月 1

指紋

Neoplasms
Therapeutics
Carcinogenesis
Acute Promyelocytic Leukemia
Cell Cycle Checkpoints
Promyelocytic Leukemia Protein
Down-Regulation
Apoptosis
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Cancer Research

引用此文

Reineke, Eric L. ; Kao, Huang Ying. / PML : An emerging tumor suppressor and a target with therapeutic potential. 於: Cancer Therapy. 2009 ; 卷 7, 編號 ISSUE A. 頁 219-226.
@article{7d88cd1e8a294353a356bea2003a1219,
title = "PML: An emerging tumor suppressor and a target with therapeutic potential",
abstract = "Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Many of these effects are due to changes in the transcriptional profile of the cell as a result of decreased size and number of PML nuclear bodies. Several mouse studies confirm the contribution of PML to oncogenesis and cancer progression. It is important to not only further define a role for PML as a tumor suppressor, but also to begin to develop strategies to target PML therapeutically.",
author = "Reineke, {Eric L.} and Kao, {Huang Ying}",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "219--226",
journal = "Cancer Therapy",
issn = "1543-9135",
publisher = "Gene Therapy Press",
number = "ISSUE A",

}

PML : An emerging tumor suppressor and a target with therapeutic potential. / Reineke, Eric L.; Kao, Huang Ying.

於: Cancer Therapy, 卷 7, 編號 ISSUE A, 01.01.2009, p. 219-226.

研究成果: Review article

TY - JOUR

T1 - PML

T2 - An emerging tumor suppressor and a target with therapeutic potential

AU - Reineke, Eric L.

AU - Kao, Huang Ying

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Many of these effects are due to changes in the transcriptional profile of the cell as a result of decreased size and number of PML nuclear bodies. Several mouse studies confirm the contribution of PML to oncogenesis and cancer progression. It is important to not only further define a role for PML as a tumor suppressor, but also to begin to develop strategies to target PML therapeutically.

AB - Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Many of these effects are due to changes in the transcriptional profile of the cell as a result of decreased size and number of PML nuclear bodies. Several mouse studies confirm the contribution of PML to oncogenesis and cancer progression. It is important to not only further define a role for PML as a tumor suppressor, but also to begin to develop strategies to target PML therapeutically.

UR - http://www.scopus.com/inward/record.url?scp=69949164620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949164620&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:69949164620

VL - 7

SP - 219

EP - 226

JO - Cancer Therapy

JF - Cancer Therapy

SN - 1543-9135

IS - ISSUE A

ER -